IL97054A - Pharmaceutical preparations containing bospirone for the treatment of coma - Google Patents

Pharmaceutical preparations containing bospirone for the treatment of coma

Info

Publication number: IL97054A
Authority: IL; Israel
Prior art keywords: buspirone; sleep; treatment; sleep apneas; apneas
Prior art date: 1990-02-12

Application number

IL9705491A

Other languages

English (en)

Hebrew (he)

Other versions

IL97054A0 (en

Original Assignee

Bristol Meyers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-02-12

Filing date

1991-01-25

Publication date

1995-10-31

1991-01-25 Application filed by Bristol Meyers Squibb Co filed Critical Bristol Meyers Squibb Co

1992-03-29 Publication of IL97054A0 publication Critical patent/IL97054A0/xx

1995-10-31 Publication of IL97054A publication Critical patent/IL97054A/en

Links

201000002859 sleep apnea Diseases 0.000 title claims abstract description 25
238000011282 treatment Methods 0.000 title claims abstract description 16
239000008194 pharmaceutical composition Substances 0.000 title claims description 8
QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 claims abstract description 33
229960002495 buspirone Drugs 0.000 claims abstract description 28
150000003839 salts Chemical class 0.000 claims abstract description 6
239000004480 active ingredient Substances 0.000 claims description 6
239000000203 mixture Substances 0.000 claims description 6
239000002253 acid Substances 0.000 claims description 5
229960001768 buspirone hydrochloride Drugs 0.000 claims description 5
208000008784 apnea Diseases 0.000 description 6
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
208000001797 obstructive sleep apnea Diseases 0.000 description 4
229910052760 oxygen Inorganic materials 0.000 description 4
239000001301 oxygen Substances 0.000 description 4
230000029058 respiratory gaseous exchange Effects 0.000 description 4
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
239000000463 material Substances 0.000 description 3
230000000414 obstructive effect Effects 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
239000000243 solution Substances 0.000 description 3
PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
206010022998 Irritability Diseases 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
208000034972 Sudden Infant Death Diseases 0.000 description 2
206010042440 Sudden infant death syndrome Diseases 0.000 description 2
239000003708 ampul Substances 0.000 description 2
239000000935 antidepressant agent Substances 0.000 description 2
229940005513 antidepressants Drugs 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
229940075614 colloidal silicon dioxide Drugs 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
206010016256 fatigue Diseases 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
238000005259 measurement Methods 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000000583 progesterone congener Substances 0.000 description 2
239000004089 psychotropic agent Substances 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
239000003169 respiratory stimulant agent Substances 0.000 description 2
229940066293 respiratory stimulants Drugs 0.000 description 2
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
229960000278 theophylline Drugs 0.000 description 2
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
-1 8- [4- [4-( 1-pyrimidinyl )-l-piperazinyl]butyl] -8-azaspiro[4,5]decane-7,9-dione hydrochloride Chemical compound 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
206010020400 Hostility Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000019430 Motor disease Diseases 0.000 description 1
201000001880 Sexual dysfunction Diseases 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
206010067775 Upper airway obstruction Diseases 0.000 description 1
206010001584 alcohol abuse Diseases 0.000 description 1
208000025746 alcohol use disease Diseases 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
230000037007 arousal Effects 0.000 description 1
230000000721 bacterilogical effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229940060734 buspirone hydrochloride 5 mg Drugs 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
208000018875 hypoxemia Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
206010025482 malaise Diseases 0.000 description 1
230000015654 memory Effects 0.000 description 1
238000000034 method Methods 0.000 description 1
208000019906 panic disease Diseases 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000000506 psychotropic effect Effects 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
229940125723 sedative agent Drugs 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
231100000872 sexual dysfunction Toxicity 0.000 description 1
230000006403 short-term memory Effects 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
208000022925 sleep disturbance Diseases 0.000 description 1
230000004622 sleep time Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
238000011277 treatment modality Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

IL9705491A 1990-02-12 1991-01-25 Pharmaceutical preparations containing bospirone for the treatment of coma IL97054A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US47980390A	1990-02-12	1990-02-12

Publications (2)

Publication Number	Publication Date
IL97054A0 IL97054A0 (en)	1992-03-29
IL97054A true IL97054A (en)	1995-10-31

Family

ID=23905511

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9705491A IL97054A (en)	1990-02-12	1991-01-25	Pharmaceutical preparations containing bospirone for the treatment of coma

Country Status (12)

Country	Link
EP (1)	EP0442423B1 (fr)
JP (1)	JP3168543B2 (fr)
KR (1)	KR910015300A (fr)
AT (1)	ATE116854T1 (fr)
CA (1)	CA2036055A1 (fr)
DE (1)	DE69106543T2 (fr)
DK (1)	DK0442423T3 (fr)
ES (1)	ES2069758T3 (fr)
GR (1)	GR3015716T3 (fr)
HK (1)	HK1005016A1 (fr)
HU (1)	HUT56496A (fr)
IL (1)	IL97054A (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5631017A (en) *	1993-03-26	1997-05-20	Beth Israel Deaconess Medical Center, Inc.	Topical application of buspirone for treatment of pathological conditions associated with immune responses
US5484788A (en) *	1993-03-26	1996-01-16	Beth Israel Hospital Association	Buspirone as a systemic immunosuppressant
US5637314A (en) *	1995-06-07	1997-06-10	Beth Israel Deaconess Medical Center, Inc.	Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
DK1066036T3 (da) *	1998-02-27	2006-08-21	Univ Illinois	Midler med serotoninrelateret aktivitet til behandling af sövnapnö
US7160898B2 (en)	2001-12-14	2007-01-09	Board Of Trustees Of The University Of Illinois	Pharmacological treatment for sleep apnea
US8134029B2 (en)	2002-09-16	2012-03-13	Sunovion Pharmaceuticals Inc.	Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
CN101132777A (zh)	2004-12-20	2008-02-27	科利吉姆制药公司	用于睡眠障碍的药物组合物
JP2009500425A (ja)	2005-07-06	2009-01-08	セプラコアインコーポレーテッド	エスゾピクロン及びトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−ｎ−メチル−１−ナフタレンアミン又はトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法
DK2816024T3 (en)	2006-03-31	2017-10-30	Sunovion Pharmaceuticals Inc	CHIRALE AMINER
JP2012526832A (ja) *	2009-05-13	2012-11-01	スノビオンプハルマセウトイカルスインコーポレイテッド	トランスノルセルトラリン及びセロトニン受容体１ａ作動剤／拮抗剤を含む組成物及びその使用

1991
- 1991-01-25 IL IL9705491A patent/IL97054A/en not_active IP Right Cessation
- 1991-02-06 JP JP10059991A patent/JP3168543B2/ja not_active Expired - Fee Related
- 1991-02-08 CA CA002036055A patent/CA2036055A1/fr not_active Abandoned
- 1991-02-11 AT AT91101888T patent/ATE116854T1/de not_active IP Right Cessation
- 1991-02-11 EP EP91101888A patent/EP0442423B1/fr not_active Expired - Lifetime
- 1991-02-11 ES ES91101888T patent/ES2069758T3/es not_active Expired - Lifetime
- 1991-02-11 KR KR1019910002288A patent/KR910015300A/ko not_active Withdrawn
- 1991-02-11 HU HU91436A patent/HUT56496A/hu unknown
- 1991-02-11 DK DK91101888.5T patent/DK0442423T3/da active
- 1991-02-11 DE DE69106543T patent/DE69106543T2/de not_active Expired - Fee Related
1995
- 1995-04-07 GR GR950400847T patent/GR3015716T3/el unknown
1998
- 1998-05-15 HK HK98104204A patent/HK1005016A1/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
JP3168543B2 (ja)	2001-05-21
HU910436D0 (en)	1991-08-28
HUT56496A (en)	1991-09-30
IL97054A0 (en)	1992-03-29
CA2036055A1 (fr)	1991-08-13
EP0442423B1 (fr)	1995-01-11
DE69106543D1 (de)	1995-02-23
EP0442423A1 (fr)	1991-08-21
ES2069758T3 (es)	1995-05-16
JPH0826997A (ja)	1996-01-30
HK1005016A1 (en)	1998-12-18
KR910015300A (ko)	1991-09-30
GR3015716T3 (en)	1995-07-31
DK0442423T3 (da)	1995-03-20
ATE116854T1 (de)	1995-01-15
DE69106543T2 (de)	1995-05-11

Legal Events

Date	Code	Title
1996-03-31	FF	Patent granted
1997-04-15	KB	Patent renewed
2001-06-14	KB	Patent renewed
2005-11-20	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
US6432956B1 (en)	2002-08-13	Method for treatment of sleep apneas
US20220151975A1 (en)	2022-05-19	Low-Dose Doxepin For Treatment Of Sleep Disorders In Elderly Patients
EP1001760B1 (fr)	2005-02-02	Composition permettant de controler les problemes d'humeur chez des individus sains
US4640921A (en)	1987-02-03	Treatment of sexual dysfunction with buspirone
TW200400821A (en)	2004-01-16	Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
IL97054A (en)	1995-10-31	Pharmaceutical preparations containing bospirone for the treatment of coma
TW201929859A (zh)	2019-08-01	夜間頻尿治療劑
HK1005016B (en)	1998-12-18	Use of buspirone in sleep apneas
IL97053A (en)	1995-10-31	Pharmaceutical preparations containing azapyrone for the treatment of coma
Campbell	1948	Inhibition of anaphylactic shock by acetylsalicylic acid
Pascoe et al.	1994	Arterial hypertension associated with topical ocular use of phenylephrine in dogs
EA006776B1 (ru)	2006-04-28	Фармацевтическая композиция для лечения диабетической невропатии
WO2000006163A1 (fr)	2000-02-10	Methode amelioree de traitement de troubles respiratoires lies au sommeil
Gray et al.	1957	Protoveratrine A in treatment of hypertension
Gale	1959	The clinical use of methylphenidate for central stimulation in oversedated patients
US2995489A (en)	1961-08-08	Method of obtaining preanesthetic sedation and drying with 1-(2-diethylaminoethyl)-5-ethyl-5-phenylbarbituric acid
JPH04282313A (ja)	1992-10-07	血圧降下剤
Wallace	1960	Preanesthetic medication without narcotics: use of promethazine and a sympathomimetic agent in 5,500 patients
Krasno et al.	1948	The Inhalation of Norisodrine Sulfate Dust
US20110076334A1 (en)	2011-03-31	Methods and compositions for treatment of raynaud's phenomenon
Committee on Drugs	1992	Precautions concerning the use of theophylline
Rethwilm	1930	SODIUM ISOAMYLETHYL BARBITURATE: REPORT ON ITS USE AS AN AUXILIARY ANESTHETIC
Booker	1996	Blastomycosis-induced respiratory failure: The successful application of continuous positive airway pressure
JPH0219318A (ja)	1990-01-23	疝痛及び生歯に対する治療
Vanhaesebrouck et al.	0	Case report: Neonatal transient respiratory depression after maternal urapidil infusion for hypertension